«

»

Mar 31

March’s top stories: Novartis’ Phase III study, Boehringer’s Respimat trial

Novartis’ Phase III study of Jakavi met its primary endpoint of maintaining haematocrit control without the need for phlebotomy and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea while Boehringer rep… (Source: Drug Development Technology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>